Metacrine (MTCR) Commences Phase 2a Trial of MET642 for Treatment of Patients with NASH

Go back to Metacrine (MTCR) Commences Phase 2a Trial of MET642 for Treatment of Patients with NASH

Metacrine Initiates Phase 2a Trial of MET642 for the Treatment of Patients with NASH

March 9, 2021 6:30 AM EST

SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the first patient has been treated in its Phase 2a trial of MET642, a potent, sustained, non-bile acid farnesoid x-receptor (FXR) agonist, for the treatment of patients with non-alcoholic steatohepatitis (NASH).

NASH is a devastating disease, for which an optimized FXR agonist could play a foundational role in the treatment paradigm, said Hubert C. Chen, M.D., chief medical... More